Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies

被引：1
|
作者：
Kuboki, Yasutoshi [1 ]
Furukawa, Masayuki [2 ]
Takahashi, Yasuo [3 ]
Mizuno, Nobumasa [4 ]
Hara, Hiroki [5 ]
Ueno, Makoto [6 ]
Ioka, Tatsuya [7 ]
Takahashi, Shunji [8 ]
Shimizu, Toshio [9 ]
Lihou, Christine F. [10 ]
Tian, Chenwei [10 ]
Ji, Tao [10 ]
Fujiwara, Yutaka [9 ]
机构：
[1] Natl Canc Cent Hosp East, Kashiwa, Chiba, Japan
[2] Kyushu Canc Ctr, Minami Ku, Fukuoka, Fukuoka, Japan
[3] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[4] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[5] Saitama Canc Ctr, Saitama, Japan
[6] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[7] Osaka Int Canc Inst, Osaka, Japan
[8] JFCR, Canc Inst Hosp, Koto Ku, Tokyo, Japan
[9] Natl Canc Ctr, Chuo Ku, Tokyo, Japan
[10] Incyte Corp, Wilmington, DE USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz343.034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1 - 156
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies
    Fujiwara, Yukata
    Kuboki, Yasutoshi
    Furukawa, Masayuki
    Mizuno, Nobumasa
    Hara, Hiroki
    Ioka, Tatsuya
    Ueno, Makoto
    Takahashi, Yasuo
    Takahashi, Shunji
    Takeuchi, Shinji
    Lihou, Christine
    Ji, Tao
    Tian, Chenwei
    Shimizu, Toshio
    CANCER MEDICINE, 2023, 12 (09): : 10597 - 10611
  • [2] Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.
    Gutierrez, Martin
    Subbiah, Vivek
    Nemunaitis, John J.
    Mettu, Niharika B.
    Papadopoulos, Kyriakos P.
    Barve, Minal A.
    Feliz, Luis
    Lihou, Christine Francis
    Tian, Chenwei
    Ji, Tao
    Silverman, Ian M.
    Chugh, Rashmi
    Saleh, Mansoor N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] A phase 1 study evaluating preliminary safety, pharmacokinetic and pharmacodynamic of pemigatinib in Chinese patients with advanced malignancy.
    Ba, Yi
    Deng, Ting
    Shi, Yehui
    Zhang, Le
    Bai, Guiying
    Pan, Yueyin
    Shen, Aizong
    Han, Xinghua
    Yang, Zhaoyi
    Cao, Lian
    Luo, Yang
    Wang, Yan
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies
    Subbiah, Vivek
    Barve, Minal
    Iannotti, Nicholas O.
    Gutierrez, Martin
    Smith, David C.
    Roychowdhury, Sameek
    Papadopoulos, Kyriakos P.
    Mettu, Niharika
    Edenfield, William J.
    Morgensztern, Daniel
    Feliz, Luis
    Lihou, Christine
    Zhen, Huiling
    Saleh, Mansoor
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [5] Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
    Shigehisa Kitano
    Toshio Shimizu
    Takafumi Koyama
    Takahiro Ebata
    Satoru Iwasa
    Shunsuke Kondo
    Akihiko Shimomura
    Yutaka Fujiwara
    Noboru Yamamoto
    Anne Paccaly
    Siyu Li
    Petra Rietschel
    Tasha Sims
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 53 - 64
  • [6] Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
    Kitano, Shigehisa
    Shimizu, Toshio
    Koyama, Takafumi
    Ebata, Takahiro
    Iwasa, Satoru
    Kondo, Shunsuke
    Shimomura, Akihiko
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Paccaly, Anne
    Li, Siyu
    Rietschel, Petra
    Sims, Tasha
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (01) : 53 - 64
  • [7] Positive updated Results from Phase II Pemigatinib Study in Patients with previously treated advanced Bile Duct Cancer
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (11) : 618 - 618
  • [8] Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
    Naito, Yoichi
    Nakamura, Seigo
    Kawaguchi-Sakita, Nobuko
    Ishida, Takanori
    Nakayama, Takahiro
    Yamamoto, Yutaka
    Masuda, Norikazu
    Matsumoto, Koji
    Kogawa, Takahiro
    Sudo, Kazuki
    Shimomura, Akihiko
    Lai, Catherine
    Zhang, Danjie
    Iwahori, Yuki
    Gary, Dianna
    Huynh, Danh
    Iwata, Hiroji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (11) : 1684 - 1695
  • [9] Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: Final results from FIGHT-202
    Vogel, A.
    Sahai, V.
    Hollebecque, A.
    Vaccaro, G.
    Melisi, D.
    Al-Rajabi, R.
    Paulson, S.
    Borad, M.
    Gallinson, D.
    Murphy, A.
    Oh, D.
    Dotan, E.
    Catenacci, D.
    Van Cutsem, E.
    Lihou, C.
    Zhen, H.
    Veronese, L.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2022, 33 : S379 - S379
  • [10] FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
    Vogel, A.
    Sahai, V.
    Hollebecque, A.
    Vaccaro, G.
    Melisi, D.
    Al-Rajabi, R.
    Paulson, A. S.
    Borad, M. J.
    Gallinson, D.
    Murphy, A. G.
    Oh, D-Y.
    Dotan, E.
    Catenacci, D. V.
    Van Cutsem, E.
    Lihou, C. F.
    Zhen, H.
    Feliz, L.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30 : 876 - 876
12345